# 3EO Health

> 3EO Health is a Beverly, Massachusetts molecular diagnostics company that built the first point-of-care molecular test priced under $15. Spun out of Harvard's Wyss Institute, its proprietary 3TR amplification technology delivers PCR-level sensitivity without sample preparation, expensive consumables, or complex lab equipment - putting molecular-grade testing in clinics, workplaces, and homes. The company calls itself a 'Point of Life' diagnostics company on a mission to democratize access to high-quality testing.

- **Founded:** 2021
- **Headquarters:** Beverly, Massachusetts, United States
- **Founders:** Peng Yin (Scientific Founder; Wyss Institute Core Faculty, Professor of Systems Biology at Harvard Medical School), Thomas Schaus (Co-Founder; Director of Research), Nikhil Gopalkrishnan (Co-Founder; core technology developer)
- **Team size:** ~19 employees
- **Products:** 3EO Health COVID-19 Test, 3TR High Efficiency Molecular Platform, Direct-to-test workflow
- **Notable:** First point-of-care molecular test priced under $15 ($14.95 per test)., Received FDA Emergency Use Authorization for its COVID-19 molecular test in Q4 2023., Reported cost per test up to 70% lower than existing molecular technologies.

## Products & services

- **3EO Health COVID-19 Test** — An FDA Emergency Use Authorized molecular test for SARS-CoV-2 from nasal swabs. Returns results in about 30 minutes; in a clinical study it correctly identified 95% of positive samples and 100% of negative samples versus an FDA-authorized molecular laboratory test.
- **3TR High Efficiency Molecular Platform** — A portable platform with a reusable base unit and pathogen-specific, single-use consumables. Its 3TR amplification technology eliminates the need for sample preparation, expensive consumables, and complex equipment, enabling low-cost, easy-to-use molecular testing under $20 per test.
- **Direct-to-test workflow** — A sample-to-result workflow that removes mixing, pipetting, and technique-dependent manual steps, designed so non-specialists can run molecular tests at the point of care or at home.

## Achievements

- First point-of-care molecular test priced under $15 ($14.95 per test).
- Received FDA Emergency Use Authorization for its COVID-19 molecular test in Q4 2023.
- Reported cost per test up to 70% lower than existing molecular technologies.
- Clinical study: 95% positive percent agreement, 100% negative percent agreement vs. an FDA-authorized lab molecular test.
- Selected for the 2023 MedTech Innovator Accelerator program.
- Received an NIH RADx Tech award to broaden its 3TR platform applications.

## Latest updates

- **2023-10** — Received FDA Emergency Use Authorization and launched its point-of-care molecular technology.
- **2023-10** — Received an NIH RADx Tech award to expand applications of its 3TR technology.
- **2024-01** — Announced the U.S. launch of the first 'High Efficiency' molecular platform.
- **2024-03** — Announced the first point-of-care molecular test under $15 ($14.95 per test).

## Links

- Website: https://3eohealth.com
- LinkedIn: https://www.linkedin.com/company/3eohealth
- Twitter/X: https://twitter.com/3eohealth

---

Profile page: https://yespress.io/3eo-health
Published by YesPress — https://yespress.io
Last updated: 2026-06-07